{"id":"lansoprazole-bismuth-subsalicylate-metronidazole-tetracycline","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Nausea"},{"rate":"10-25","effect":"Diarrhea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"10-20","effect":"Metallic taste (metronidazole)"},{"rate":"5-10","effect":"Photosensitivity (tetracycline)"},{"rate":"5-10","effect":"Headache"},{"rate":"common but benign","effect":"Black stool (bismuth)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion, creating an inhospitable environment for H. pylori. Bismuth subsalicylate provides direct antimicrobial activity against the bacteria. Metronidazole and tetracycline are antibiotics that target bacterial DNA replication and protein synthesis, respectively, working synergistically to eliminate the infection.","oneSentence":"This quadruple therapy combination eradicates Helicobacter pylori by reducing gastric acid, disrupting bacterial cell membranes, and inhibiting bacterial protein synthesis and DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:15.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"},{"name":"Peptic ulcer disease associated with H. pylori"}]},"trialDetails":[{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline","genericName":"Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline","companyName":"Soroka University Medical Center","companyId":"soroka-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This quadruple therapy combination eradicates Helicobacter pylori by reducing gastric acid, disrupting bacterial cell membranes, and inhibiting bacterial protein synthesis and DNA replication. Used for Helicobacter pylori infection eradication, Peptic ulcer disease associated with H. pylori.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}